HER2 status-Negative Posts on Medivizor
Navigation Menu

HER2 status-Negative Posts on Medivizor

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Evaluating radiation therapy after breast removal surgery for node-positive triple-negative breast cancer.

Evaluating radiation therapy after breast removal surgery for node-positive triple-negative breast cancer.

Posted by on Dec 28, 2020 in Breast cancer | 0 comments

In a nutshell This study was carried out to assess the use of radiotherapy (RT) after mastectomy (surgical removal of the breast) for triple-negative breast cancer (TNBC) that has spread to the lymph nodes. The authors found that RT after surgery was associated with improved survival in patients with larger tumors. Some background Triple-negative...

Read More

Chemotherapy improves triple-negative breast cancer survival in older women

Chemotherapy improves triple-negative breast cancer survival in older women

Posted by on Dec 27, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at the outcomes of older women with triple-negative breast cancer who received chemotherapy before or after local treatment. The data showed that chemotherapy can be considered in the treatment of these patients. Some background Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that tests...

Read More

Searching for patients with metastatic breast cancer to trial a targeted therapy

Searching for patients with metastatic breast cancer to trial a targeted therapy

Posted by on Dec 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...

Read More

Evaluating olaparib for metastatic breast cancer with BRCA1/2 and other gene mutations.

Evaluating olaparib for metastatic breast cancer with BRCA1/2 and other gene mutations.

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the effectiveness of olaparib (Lynparza) for the treatment of metastatic breast cancer (MBC; cancer that has spread) with gene mutations (abnormalities). The authors found that this treatment was effective for patients with MBC with BRCA1/2 mutations. Some background Breast cancer (BC) is one of the...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Breast cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Searching for patients with metastatic triple negative breast cancer to trial a cancer vaccine

Searching for patients with metastatic triple negative breast cancer to trial a cancer vaccine

Posted by on Nov 9, 2020 in Breast cancer | 0 comments

In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...

Read More

Evaluating the addition of veliparib to platinum-based chemotherapy for BRCA-positive advanced breast cancer.

Evaluating the addition of veliparib to platinum-based chemotherapy for BRCA-positive advanced breast cancer.

Posted by on Oct 18, 2020 in Breast cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness and safety of veliparib (ABT-888) in combination with carboplatin (Paraplatin) and paclitaxel (Taxol) in BRCA-mutated advanced breast cancer (BC). The authors found that the addition of veliparib to platinum-based chemotherapy resulted...

Read More

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Posted by on Oct 11, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of atezolizumab (Tecentriq) as an addition to chemotherapy before surgery for patients with early-stage triple-negative breast cancer (TNBC). The data showed that the combination is effective in improving treatment response in these patients. Some background...

Read More

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Posted by on Sep 6, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...

Read More